BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
Rhea-AI Summary
BeyondSpring (NASDAQ:BYSI) reported Q1 2026 results and pipeline updates. Continuing operations showed R&D and G&A expenses of $1.1M each, net loss of $2.4M, and $7.9M in cash and investments.
Plinabulin preclinical data supported its use with ADCs, while SEED’s ST-01156 entered Phase 1 with biomarker-driven development.
AI-generated analysis. Not financial advice.
Positive
- Plinabulin preclinical ADC combinations improved response, survival, tolerability, and CD8+/Treg ratio
- ST-01156 RBM39 molecular glue advanced into Phase 1; first dose cohort completed
- AACR 2026 data showed complete tumor eradication in a neuroblastoma in vivo model
- G&A expenses from continuing operations fell to $1.1M from $1.7M year over year
- Net loss from continuing operations narrowed to $2.4M from $2.6M year over year
Negative
- Net loss from continuing operations was $2.4M in Q1 2026
- Discontinued operations recorded a $4.3M net loss versus $3.8M net income a year earlier
- R&D expenses from continuing operations increased to $1.1M from $0.9M year over year
News Market Reaction – BYSI
On the day this news was published, BYSI gained 4.32%, reflecting a moderate positive market reaction. Argus tracked a peak move of +5.2% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $3M to the company's valuation, bringing the market cap to $66.61M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
BYSI is down 8.55% while key biotech peers show mixed moves: IMMX up 6.81%, ALGS up 4.19%, OSTX down 1.72%, ACET down 2.69%, IGMS down 2.31%. Combined with scanner data showing only OSTX in momentum, the pattern points to a stock-specific reaction.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 25 | Year-end earnings | Positive | +3.7% | 2025 year-end results with Phase 3 success and SEED progress highlighted. |
| Nov 12 | Q3 2025 earnings | Positive | -3.6% | Q3 2025 data showing strong NSCLC metrics and SEED financing progress. |
| Aug 13 | Q2 2025 earnings | Positive | -0.5% | Q2 2025 update with promising Plinabulin data and SEED IND clearance. |
| May 12 | Q1 2025 earnings | Positive | +4.3% | Q1 2025 results plus early clinical success and SEED pipeline advances. |
Earnings-related releases have produced mixed reactions, with two positive and two negative 24-hour moves despite generally constructive clinical and financial updates.
Over the past year, BeyondSpring’s earnings updates have consistently paired oncology progress with evolving financials. The Q2 2025 and Q3 2025 results highlighted Plinabulin’s activity in NSCLC and multiple cancer types, plus SEED’s RBM39 degrader advances and financings. The 2025 year-end release emphasized positive Phase 3 DUBLIN-3 data, plans for DUBLIN-4, and cash of $12.6M as of Dec 31, 2025. Today’s Q1 2026 update continues this pattern, showing modestly lower net loss and focused R&D and G&A spending alongside pipeline momentum.
Historical Comparison
In the past four earnings releases, BYSI’s average 24-hour move was 0.95%, with reactions split between gains and losses. Today’s sharper -8.55% drop stands out versus that history.
Earnings updates trace Plinabulin’s evolution from Phase 1–2 signals to Phase 3 DUBLIN-3 success and a planned DUBLIN-4 trial, while SEED’s RBM39 degrader advanced from IND clearance into Phase 1 and attracted Series A-3 financing.
Market Pulse Summary
This announcement combines Q1 2026 financial results with pipeline updates for Plinabulin and SEED’s RBM39 degrader ST‑01156. BeyondSpring reported R&D and G&A expenses of $1.1M each, a net loss from continuing operations of $2.4M, cash of $7.9M, and a $4.3M loss from discontinued operations. Historically, earnings updates have intertwined clinical milestones and funding needs, so investors may watch burn trends, SEED’s discontinued-operations performance, and progress into Phase 3 and Phase 1 trials as key future catalysts.
Key Terms
antibody-drug conjugate (ADC) medical
molecular glue degrader medical
biomarker-driven medical
immune checkpoint inhibitors medical
CD8+ T cell / Treg ratio medical
Phase 1 clinical development medical
discontinued operations financial
ASC 205-20 regulatory
AI-generated analysis. Not financial advice.
AACR 2026 Data Positions Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC)-Based Therapies to Improve Anti-Cancer Efficacy and Tolerability
SEED Advances First Molecular Glue Degrader into Clinical Development with Biomarker-Driven Strategy
FLORHAM PARK, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced its financial results for the quarter ended March 31, 2026, and provided a corporate update highlighting significant scientific and clinical advancements across its pipeline.
“Plinabulin continues to demonstrate the ability to enhance both efficacy and tolerability in ADC-based regimens, supporting its positioning as a potential backbone agent across a rapidly evolving treatment landscape,” said Dr. Lan Huang, Co-Founder, Chair, and Chief Executive Officer of BeyondSpring. “Data presented at AACR 2026 further highlights the expanding value of our pipeline and reinforces our strategy of advancing highly differentiated therapies with the potential to address significant unmet medical needs. We believe Plinabulin has the potential to become a foundational combination agent that unlocks the full clinical and commercial value of ADC therapies.”
Dr. Huang continued, “At SEED, the advancement of ST-01156, a novel RBM39 molecular glue degrader, into clinical development in oncology indications, coupled with a biomarker-driven approach, underscores the strength and scalability of our RITE3™ platform. These milestones reflect disciplined execution across our portfolio and position us to unlock meaningful long-term value through multiple clinical and strategic partnership opportunities.”
Recent Clinical Highlights
Plinabulin: Expanding Role as a Potentially Foundational Combination Therapy
- AACR 2026 data demonstrated that Plinabulin significantly enhances both efficacy and tolerability of topoisomerase inhibitor–based ADC regimens, with or without immune checkpoint inhibitors
- Preclinical findings showed:
- Improved complete response rate and survival outcomes
- Improved tolerability
- Enhanced CD8+ T cell / Treg ratio - shifting the tumor immune environment from suppression to attack
- These preclinical results suggest Plinabulin’s potential to address key limitations of current ADC therapies, including limited durability and dose-limiting safety concerns, and support Plinabulin’s positioning as a potential backbone agent across a broad range of ADC combination regimens
SEED Therapeutics: Advancing precision oncology through molecular glue degraders
- ST-01156 (RBM39 molecular glue degrader) advanced into Phase 1 clinical development, with the first dose cohort completed
- AACR 2026 data demonstrated:
- Complete tumor eradication in a neuroblastoma in vivo model
- Identification of MYC overexpression and CDKN2A/B deletion as potential predictive biomarkers
- This program represents a biomarker-driven precision oncology approach and highlights the productivity of SEED’s proprietary RITE3™ platform for targeted protein degradation
First Quarter Financial Results1
Continuing operations:
- R&D expenses were
$1.1 million for the three months ended March 31, 2026 compared to$0.9 million for the three months ended March 31, 2025. The$0.2 million increase was primarily driven by increased drug manufacturing activities to prepare for potential future study initiation, partially offset by lower regulatory filing advisory and personnel expenses - G&A expenses were
$1.1 million for the three months ended March 31, 2026 compared to$1.7 million for the three months ended March 31, 2025. The$0.6 million decrease was primarily driven by lower personnel and legal advisory expenses - Net loss was
$2.4 million for the three months ended March 31, 2026 compared to$2.6 million for the three months ended March 31, 2025 - Cash, cash equivalents, and short-term investments were
$7.9 million as of March 31, 2026
Discontinued operations:
- Net loss was
$4.3 million for the three months ended March 31, 2026, compared to net income of$3.8 million for the three months ended March 31, 2025 - Current assets were
$5.3 million as of March 31, 2026
Note 1. As a result of BeyondSpring entering into definitive agreements to sell a portion of its Series A-1 Preferred Shares of SEED, SEED’s operations met the criteria as discontinued operations under ASC 205-20 for financial reporting purposes.
About BeyondSpring
BeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies for cancers with high unmet need. Its lead asset, Plinabulin, has been studied in over 700 cancer patients and is in late-stage development across multiple cancer indications, with results published in The Lancet Respiratory Medicine. Learn more at beyondspringpharma.com.
About SEED Therapeutics
SEED Therapeutics is a clinical-stage biotechnology company pioneering targeted protein degradation. Its proprietary RITE3™ platform is advancing novel molecular glue degraders across oncology, neurodegeneration, and immunology. SEED collaborates with Eli Lilly and Company and Eisai Co., Ltd., and is advancing its RBM39 degrader into clinical development. Learn more at seedtherapeutics.com.
Investor Contact: IR@beyondspringpharma.com
Media Contact: PR@beyondspringpharma.com
Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements that are not historical facts. Words such as “will,” “expect,” “anticipate,” “plan,” “believe,” “design,” “may,” “future,” “estimate,” “predict,” “objective,” “goal,” or variations thereof and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring’s current knowledge, beliefs, and expectations regarding possible future events and are subject to risks, uncertainties, and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including, but not limited to, difficulties raising the anticipated amount needed to finance the Company’s future operations on terms acceptable to the Company, if at all; unexpected results from preclinical studies or clinical trials; the risk that preclinical results may not be predictive of clinical results; delays in, or failure to obtain, regulatory approvals; results that do not meet the Company’s expectations regarding the safety, efficacy, clinical utility, or regulatory pathway of the Company’s product candidates; increased competition in the market; the Company’s ability to meet Nasdaq’s continued listing requirements; and other risks described in BeyondSpring’s most recent Form 10-K and subsequent filings with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release, and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
Financial Tables to Follow
| BEYONDSPRING INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts in thousands of U.S. Dollars (“$”), except for number of shares and per share data) | ||||||||
| As of | ||||||||
| December 31, 2025 | March 31, 2026 | |||||||
| $ | $ | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | 7,786 | 4,036 | ||||||
| Short-term investments | 4,775 | 3,827 | ||||||
| Advances to suppliers | 227 | 177 | ||||||
| Prepaid expenses and other current assets | 71 | 181 | ||||||
| Current assets of discontinued operations | 8,023 | 5,283 | ||||||
| Total current assets | 20,882 | 13,504 | ||||||
| Noncurrent assets: | ||||||||
| Property and equipment, net | 166 | 152 | ||||||
| Operating right-of-use assets | 305 | 240 | ||||||
| Other noncurrent assets | 224 | 126 | ||||||
| Noncurrent assets of discontinued operations | 4,356 | 4,384 | ||||||
| Total noncurrent assets | 5,051 | 4,902 | ||||||
| Total assets | 25,933 | 18,406 | ||||||
| Liabilities and equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | 363 | 646 | ||||||
| Accrued expenses | 938 | 1,278 | ||||||
| Current portion of operating lease liabilities | 320 | 246 | ||||||
| Other current liabilities | 822 | 937 | ||||||
| Current liabilities of discontinued operations | 11,133 | 9,263 | ||||||
| Total current liabilities | 13,576 | 12,370 | ||||||
| Noncurrent liabilities: | ||||||||
| Deferred revenue | 28,600 | 28,994 | ||||||
| Other noncurrent liabilities | 3,981 | 4,239 | ||||||
| Noncurrent liabilities of discontinued operations | 3,766 | 3,157 | ||||||
| Total noncurrent liabilities | 36,347 | 36,390 | ||||||
| Total liabilities | 49,923 | 48,760 | ||||||
| Shareholders’ deficit | ||||||||
| Ordinary shares ( | 4 | 4 | ||||||
| Additional paid-in capital | 375,664 | 375,739 | ||||||
| Accumulated deficit | (408,431 | ) | (410,590 | ) | ||||
| Accumulated other comprehensive income | 602 | 360 | ||||||
| Total BeyondSpring Inc.’s shareholders’ deficit | (32,161 | ) | (34,487 | ) | ||||
| Noncontrolling interests | 8,171 | 4,133 | ||||||
| Total shareholders’ deficit | (23,990 | ) | (30,354 | ) | ||||
| Total liabilities and shareholders’ deficit | 25,933 | 18,406 | ||||||
| BEYONDSPRING INC. CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Amounts in thousands of U.S. Dollars (“$”), except for number of shares and per share data) (Unaudited) | ||||||||
| Three months ended March 31, | ||||||||
| 2025 | 2026 | |||||||
| $ | $ | |||||||
| Revenue | - | - | ||||||
| Operating expenses | ||||||||
| Research and development | (874 | ) | (1,076 | ) | ||||
| General and administrative | (1,736 | ) | (1,156 | ) | ||||
| Loss from operations | (2,610 | ) | (2,232 | ) | ||||
| Foreign exchange gain, net | 29 | 50 | ||||||
| Interest income | 17 | 8 | ||||||
| Other income, net | - | 15 | ||||||
| Loss before income tax | (2,564 | ) | (2,159 | ) | ||||
| Income tax expenses | (20 | ) | (192 | ) | ||||
| Net loss from continuing operations | (2,584 | ) | (2,351 | ) | ||||
| Discontinued operations | ||||||||
| Loss from discontinued operations | (3,232 | ) | (4,323 | ) | ||||
| Gain on sale of subsidiary interests | 6,986 | - | ||||||
| Income tax expenses | - | - | ||||||
| Net income (loss) from discontinued operations | 3,754 | (4,323 | ) | |||||
| Net income (loss) | 1,170 | (6,674 | ) | |||||
| Less: Net loss attributable to noncontrolling interests from continuing operations | (75 | ) | (132 | ) | ||||
| Less: Net loss attributable to noncontrolling interests from discontinued operations | (3,232 | ) | (4,383 | ) | ||||
| Net income (loss) attributable to BeyondSpring Inc. | 4,477 | (2,159 | ) | |||||
| Earnings (loss) per share, basic and diluted | ||||||||
| Continuing operations | (0.06 | ) | (0.05 | ) | ||||
| Discontinued operations | 0.17 | - | ||||||
| Basic and diluted earnings (loss) per share | 0.11 | (0.05 | ) | |||||
| Weighted-average shares outstanding | ||||||||
| Basic and diluted | 40,316,320 | 41,119,803 | ||||||
| Other comprehensive loss, net of tax of nil: | ||||||||
| Foreign currency translation adjustment loss from continuing operations | (151 | ) | (379 | ) | ||||
| Foreign currency translation adjustment loss from discontinued operations | (7 | ) | (47 | ) | ||||
| Comprehensive income (loss) | 1,012 | (7,100 | ) | |||||
| Less: Comprehensive loss attributable to noncontrolling interests from continuing operations | (130 | ) | (269 | ) | ||||
| Less: Comprehensive loss attributable to noncontrolling interests from discontinued operations | (3,238 | ) | (4,430 | ) | ||||
| Comprehensive income (loss) attributable to BeyondSpring Inc. | 4,380 | (2,401 | ) | |||||
